Skip to main content
. 2019 Jun 21;98(25):e16074. doi: 10.1097/MD.0000000000016074

Figure 1.

Figure 1

OS of patients with BCLC C stage HCC who underwent different sorafenib-based therapies, as assessed by Kaplan–Meier analysis. Treatment with sorafenib yielded a significantly better median OS than BSC (P < .001) (A). Sorafenib with concurrent TACE had a significantly better median OS than sorafenib alone (P = .048) (B). Sorafenib with multiple-line treatments resulted in a significantly better median OS than sorafenib alone (P < .015) (C). Sorafenib with third-line treatments yielded a significantly better median OS than sorafenib alone (P < .009) (D). BCLC = Barcelona clinic liver cancer, BSC = best supportive care, HCC = hepatocellular carcinoma, OS = overall survival, TACE = transarterial chemoembolization.